SUMMARY The in vivo production of prostacyclin and thromboxane was monitored by measuring their major urinary metabolites 2,3-dinor-thromboxane B2 and 2,3-dinor-6-ketoprostaglandin F ,I in ten patients with acute myocardial infarction, five on standard treatment and five receiving prostacyclin infusion. During acute myocardial infarction excretion of 2,3-dinor-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F,5, measured by a gas chromatography-mass spectrometry method with deuterated internal standards, was significantly -increased. This indicates that thromboxane and prostacyclin synthesis are increased during the development of acute myocardial infarction. The excretion data for 2,3-dinor-thromboxane B2 showed that after administration of aspirin there was less pronounced and more variable inhibition than expected. Prostacyclin infusion did not markedly affect the excretion of the thromboxane metabolite. Accepted for publication 25 October 1985 The in vivo metabolism of thromboxane B2 and prostacyclin has been studied in man and the main urinary metabolites have been identified as 2,3-dinor-thromboxane B2 and 2,3-dinor-6-ketoprostaglandin F1l respectively.9 10 Methods for analysis of these compounds have been developed based on deuterated internal standards/carriers and gas chromatography-mass spectrometry. 14 Excretion of those metabolites quickly (0O5-1-5 hours) and adequately reflects changes in the production of thromboxane A2 and prostacyclin in vivo.714-16 The intra-individual variation in the excretion of these metabolites is small and independent of urine production.16 The excretion of the prostacyclin metabolite is, however, considerably increased by physical exercise.14 We report on the formation of thromboxane A2 and prostacyclin in vivo during and after the development of myocardial infarction.'7
prostaglandin F ,I in ten patients with acute myocardial infarction, five on standard treatment and five receiving prostacyclin infusion. During acute myocardial infarction excretion of 2,3-dinor-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F,5, measured by a gas chromatography-mass spectrometry method with deuterated internal standards, was significantly -increased. This indicates that thromboxane and prostacyclin synthesis are increased during the development of acute myocardial infarction. The excretion data for 2,3-dinor-thromboxane B2 showed that after administration of aspirin there was less pronounced and more variable inhibition than expected. Prostacyclin infusion did not markedly affect the excretion of the thromboxane metabolite.
There has been considerable interest in the possible role of platelets in the pathogenesis of acute myocardial infarction.1 The discovery of thromboxane A2 and its vasoconstricting and platelet aggregating effects has focused attention on the possible involvement of this platelet-derived compound in cardiovascular disease. 2 Similarly the discovery of prostacyclin and its vasodilatory and platelet antiaggregatory effects triggered off intense research on the possible role of this compound in protective mechanisms against cardiovascular disease. Accepted for publication 25 October 1985 The in vivo metabolism of thromboxane B2 and prostacyclin has been studied in man and the main urinary metabolites have been identified as 2,3-dinor-thromboxane B2 and 2,3-dinor-6-ketoprostaglandin F1l respectively.9 10 Methods for analysis of these compounds have been developed based on deuterated internal standards/carriers and gas chromatography-mass spectrometry. 14 Excretion of those metabolites quickly (0O5-1-5 hours) and adequately reflects changes in the production of thromboxane A2 and prostacyclin in vivo.714-16 The intra-individual variation in the excretion of these metabolites is small and independent of urine production.16 The excretion of the prostacyclin metabolite is, however, considerably increased by physical exercise.14 We report on the formation of thromboxane A2 and prostacyclin in vivo during and after the development of myocardial infarction. ' The methods that we used to measure 2,3-dinor-thromboxane B2 and 2,3-dinor-6-ketoprostaglandin F1l in urine have been described in detail elsewhere.13 14 
Results
The 15 hours after the maximum creatine kinase MB concentration.
Patient B-Before and during the tirst 2-5 days of infusion urinary excretion of 2,3-dinor-thromboxane B2 was two to four times higher than the highest excretion seen in normal healthy females. Sixty one hours after the start of the infusion she was given 500mg of aspirin, and 4-12 hours afterwards excretion of 2,3-dinor-thromboxane B2 increased to 5646 pg/mg creatinine. This patient initially had normal urinary excretion of 2,3-dinor-6-ketoprostaglandin F1, that later increased to a peak of 3605 pg/mg creatinine. Nine months later excretion of 2,3-dinor-thromboxane B2 and 2,3-dinor-6-keto- Patient H-During the first day of prostacyclin infusion the urinary excretion rate of 2,3-dinorthromboxane B2 was clearly higher than the excretion rate in normal healthy males. Twenty eight hours after the start of the infusion the patient was started on 1 5 g aspirin daily for pericarditis. An abrupt reduction in excretion (by about 80%) followed. Eight months later excretion of the thromboxane metabolite was 320 pg/mg creatinine.
Patient I-Urinary excretion of 2,3-dinorthromboxane B2 in the initial sample was clearly higher (755 pg/mg creatinine) than that in normal healthy males. The patient received 500 mg aspirin at about 25 hours, and this reduced urinary excretion of 2,3-dinor-thromboxane B2 by 50-60%. Later the patient was given more aspirin (3 g in total) without any further reduction of the excretion of 2,3-dinor-thromboxane B2. The excretion of 2,3-dinor-thromboxane B2 seven months later was 115 pg/mg creatinine.
Patient J-The urinary excretion of 2,3-dinor-thromboxane B2 was slightly higher than group.bmj.com on October 14, 2017 -Published by http://heart.bmj.com/ Downloaded from In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction normal for most of the study. Eight months later the excretion of 2,3-dinor-thromboxane B2 was 173 pg/mg creatinine.
STATISTICAL EVALUATION
We compared the initial and follow up values on the excretion of 2,3-dinor-thromboxane B2 in the eight cases in which we were able to collect follow up samples (Fig. 3) . The mean initial excretion was 771 (410) pg/mg creatinine (mean (SD)) and the follow up excretion was 268 (167) pg/mg creatinine (mean (SD)). Student's t test for paired samples showed a highly significant difference (p<0-01) between the initial and follow up excretion.
Discussion
We found a prolonged increase in the in vivo synthesis of thromboxane and prostacyclin during the acute phase of myocardial infarction. This suggests that these substances may be involved in the pathophysiology of acute myocardial infarction.
In all patients except case F excretion of 2,3-dinor-thromboxane B2 was higher than normal during at least part of the study period. Since there is little variation (SD 10-23%) in the excretion of 2,3-dinor-thromboxane B2 in a normal individual over weeks and months, '6 we believe that the finding that maximum increases seen during the study were 2-11 times higher than those found [7] [8] [9] months later is more important than the general rise in excretion. There was also a highly significant difference between the excretion in the very first urine sample, which was collected before any treatment was started, and in that obtained [7] [8] [9] months later. Moreover the excretion in one and the same individual during the first 80 hours was very variable; the ratio between the highest and lowest values ranged from about 1-5:1 to 3-5:1 (values for case A and after aspirin are not included). Thus both the level of and the variability of the excretion of 2,3-dinor-thromboxane B2 strongly suggest the involvement of thromboxane in the pathogenesis of acute myocardial infarction.
Excretion of 2,3-dinor-6-keto-prostaglandin Fl.
in four of the cases without prostacyclin infusion was initially within the normal range. Thereafter the excretion increased, reaching a peak [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Excretion of 2,3-dinor-6-keto-prostaglandin Fl.
before infusion of prostacyclin was within normal limits and increased to about 30 000 pg/mg creatinine during infusion. The infusion had no obvious immediate effect on the excretion of the thromboxane metabolite. These data seem to contradict the idea that exogenous prostacyclin will reduce in vivo thromboxane synthesis.
Three individuals in each group were given aspirin during the study. Only three of them, E, H, and I, showed an abrupt reduction in 2,3-dinorthromboxane B2 excretion (by 65%, 82%, and 65% respectively). These values are similar to or only slightly higher than those seen in normal individuals after 500 mg of aspirin. The effect of aspirin on the excretion of 2,3-dinor-thromboxane B2 in cases A, B, and G, however, is distinctly different from that seen in normal individuals. '3 16 In case A a dose of 3 x 500mg aspirin caused a 55% decrease in urinary 2,3-dinor-thromboxane B2 from 880 to about 378 pg/mg creatinine. A further 500mg aspirin given at 69 h caused another reduction from 205 to 124 pg/mg creatinine. Patient B was given 500 mg aspirin at 61 hours when symptoms of what later turned out to be a post-myocardial infarction syndrome first appeared. The urine sample collected after this showed an enormous increase in the excretion of 2,3-dinor-thromboxane B2. Patient G developed symptoms of pericarditis around 20 hours after the start of infusion and daily doses of 8 g aspirin were given. Despite this large dose excretion of 2,3-dinor-thromboxane B2 declined only gradually to around 150pg/mg creatinine. Aspirin has less effect on thromboxane synthesis during acute myocardial infarction (that is when thromboxane synthesis seems to be raised and labile) than it does in healthy individuals.
Our data strongly indicate that synthesis of thromboxane is increased and variable for several days after acute myocardial infarction. This probably reflects a generalised increase in platelet aggregability but we cannot rule out the possibility of an increase in thromboxane synthesis when the coronary vessel becomes occluded. We can only speculate on the reasons for a very high synthesis of prostacyclin, which peaked after maximum creatine kinase MB release, but this finding could indicate
